TrialCancer medicine2018

A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.

Takayuki Ueno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.